News & analysis on the clinical development and manufacture of large molecule drugs
F-Star: Eliot Forster
By Ben Hargreaves
- Last updated on
F-star Biotechnology, based in Cambridge, UK, has instated Eliot Forster as its new CEO. Forster joins the UK biotech after having accrued a number of years’ experience as a CEO within the biopharma space.
He spent three years as CEO of Solace Pharmaceuticals, almost five years as head of Creabilis and three years as CEO at Immunocore. Prior to these positions, he had spent 11 years at Pfizer and worked at GlaxoSmithKline (GSK).
At Immunocore, his most recent position, the biotech successfully raised $320m (€282m) in a Series A financing round, as well as developing clinical collaborations with AstraZeneca, GSK and Roche in the immuno-oncology (IO) area.
F-star is also working in the IO space, focusing on modifying monoclonal antibodies (mAbs) by introducing an additional antigen-binding site in the Fc region of an antibody.
“We are delighted to welcome Eliot as F-star’s new CEO. His proven track record in leading and developing biotech IO companies will be essential in driving F-star forward to deliver the next wave of immunotherapies for cancer patients,” said Nessan Bermingham, executive chair of F-star.